Literature DB >> 16258853

Agonistic properties of cannabidiol at 5-HT1a receptors.

Ethan B Russo1, Andrea Burnett, Brian Hall, Keith K Parker.   

Abstract

Cannabidiol (CBD) is a major, biologically active, but psycho-inactive component of cannabis. In this cell culture-based report, CBD is shown to displace the agonist, [3H]8-OH-DPAT from the cloned human 5-HT1a receptor in a concentration-dependent manner. In contrast, the major psychoactive component of cannabis, tetrahydrocannabinol (THC) does not displace agonist from the receptor in the same micromolar concentration range. In signal transduction studies, CBD acts as an agonist at the human 5-HT1a receptor as demonstrated in two related approaches. First, CBD increases [35S]GTPgammaS binding in this G protein coupled receptor system, as does the known agonist serotonin. Second, in this GPCR system, that is negatively coupled to cAMP production, both CBD and 5-HT decrease cAMP concentration at similar apparent levels of receptor occupancy, based upon displacement data. Preliminary comparative data is also presented from the cloned rat 5-HT2a receptor suggesting that CBD is active, but less so, relative to the human 5-HT1a receptor, in binding analyses. Overall, these studies demonstrate that CBD is a modest affinity agonist at the human 5-HT1a receptor. Additional work is required to compare CBD's potential at other serotonin receptors and in other species. Finally, the results indicate that cannabidiol may have interesting and useful potential beyond the realm of cannabinoid receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258853     DOI: 10.1007/s11064-005-6978-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  36 in total

1.  Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum.

Authors:  Mark G Devlin; Arthur Christopoulos
Journal:  J Neurochem       Date:  2002-03       Impact factor: 5.372

2.  Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors.

Authors:  J F Cheer; A K Cadogan; C A Marsden; K C Fone; D A Kendall
Journal:  Neuropharmacology       Date:  1999-04       Impact factor: 5.250

Review 3.  Pharmacology of cannabinoid CB1 and CB2 receptors.

Authors:  R G Pertwee
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

4.  Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.

Authors:  Jonathan S Berman; Catherine Symonds; Rolfe Birch
Journal:  Pain       Date:  2004-12       Impact factor: 6.961

Review 5.  Psychopharmacology of 5-HT(1A) receptors.

Authors:  P J Cowen
Journal:  Nucl Med Biol       Date:  2000-07       Impact factor: 2.408

6.  Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.

Authors:  Derick T Wade; Petra Makela; Philip Robson; Heather House; Cynthia Bateman
Journal:  Mult Scler       Date:  2004-08       Impact factor: 6.312

7.  Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans.

Authors:  S R Wachtel; M A ElSohly; S A Ross; J Ambre; H de Wit
Journal:  Psychopharmacology (Berl)       Date:  2002-04-19       Impact factor: 4.530

8.  Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants.

Authors:  A J Hampson; M Grimaldi; J Axelrod; D Wink
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

Review 9.  Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Authors:  Ethan B Russo
Journal:  Neuro Endocrinol Lett       Date:  2004 Feb-Apr       Impact factor: 0.765

10.  Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors.

Authors:  F Petitet; B Jeantaud; M Reibaud; A Imperato; M C Dubroeucq
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

View more
  236 in total

1.  The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects.

Authors:  Maria Grazia Cascio; Erica Zamberletti; Pietro Marini; Daniela Parolaro; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2015-03       Impact factor: 8.739

2.  Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice.

Authors:  Y Avraham; Nc Grigoriadis; T Poutahidis; L Vorobiev; I Magen; Y Ilan; R Mechoulam; Em Berry
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

3.  Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.

Authors:  Abir T El-Alfy; Kelly Ivey; Keisha Robinson; Safwat Ahmed; Mohamed Radwan; Desmond Slade; Ikhlas Khan; Mahmoud ElSohly; Samir Ross
Journal:  Pharmacol Biochem Behav       Date:  2010-03-21       Impact factor: 3.533

Review 4.  Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences.

Authors:  J M McPartland; M Glass; R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-07-16       Impact factor: 8.739

5.  Unique effects of compounds active at both cannabinoid and serotonin receptors during stroke.

Authors:  Ming Zhang; Anu Mahadevan; Mukkanti Amere; Hongbo Li; Doina Ganea; Ronald F Tuma
Journal:  Transl Stroke Res       Date:  2012-07-26       Impact factor: 6.829

6.  Acute and chronic effects of cannabidiol on Δ⁹-tetrahydrocannabinol (Δ⁹-THC)-induced disruption in stop signal task performance.

Authors:  David S Jacobs; Stephen J Kohut; Shan Jiang; Spyros P Nikas; Alexandros Makriyannis; Jack Bergman
Journal:  Exp Clin Psychopharmacol       Date:  2016-08-15       Impact factor: 3.157

7.  Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors.

Authors:  T V Zanelati; C Biojone; F A Moreira; F S Guimarães; Sâmia R L Joca
Journal:  Br J Pharmacol       Date:  2009-12-04       Impact factor: 8.739

8.  A putative 'pre-nervous' endocannabinoid system in early echinoderm development.

Authors:  G A Buznikov; L A Nikitina; V V Bezuglov; M E Y Francisco; G Boysen; I N Obispo-Peak; R E Peterson; E R Weiss; H Schuel; B R S Temple; A L Morrow; J M Lauder
Journal:  Dev Neurosci       Date:  2009-11-12       Impact factor: 2.984

9.  Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.

Authors:  Robert E Vann; Thomas F Gamage; Jonathan A Warner; Ericka M Marshall; Nathan L Taylor; Billy R Martin; Jenny L Wiley
Journal:  Drug Alcohol Depend       Date:  2008-04-01       Impact factor: 4.492

Review 10.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.